Aptamer Group PLC Aptamer Group signs two substantial new contracts (6087N)

TIDMAPTA

RNS Number : 6087N

Aptamer Group PLC

24 January 2023

24 January 2023

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Aptamer Group signs two substantial new contracts

- Contracts worth over GBP500,000 with the potential for downstream milestone and royalty/ licensing payments

Aptamer Group plc (AIM: APTA), the developer of novel Optimer(R) binders to enable innovation in the life sciences industry, announces the recent signing of two new fee-for-service contracts initially worth over GBP500,000, subject to the successful progression of Optimer development, with the potential for downstream milestone and royalty/licensing payments. These latest contracts are in addition to GBP1.0m of recognised revenue in H1, as well as the additional GBP1.0m in signed orders, announced in Aptamer's recent trading update.

The first contract is with BaseCure Therapeutics, a pre-clinical stage biotech company dedicated to the discovery and development of innovative siRNA-based medicines. Aptamer is working with BaseCure Therapeutics to identify cell targeting Optimer binders that might be developed as potential delivery vehicles for siRNA uptake into target cells and tissues. The ability to achieve Optimer-directed targeted delivery would offer exciting new therapeutic opportunities of siRNA-mediated gene knockdown in these target cells and tissues.

The second contract is with a developer of custom enzymes based in Asia. Aptamer will develop Optimer binders for incorporation into a biosensor to allow convenient monitoring of the ingredients in the company's manufacturing processes. As these ingredients are typically small molecule targets, antibodies often struggle to develop the required levels of selectivity to these targets.

Dr Arron Tolley, Chief Executive Officer, commented: "Signing these two substantial deals is a solid start to the second half for Aptamer Group. The diverse nature of these partnerships demonstrates the broad applicability of the Optimer platform across the life science industry, from supporting improved manufacturing methods to developing new drugs and the increased need for novel antibody alternatives within the life science market. I look forward to updating the market regarding progress for these deals and new partnerships in due course."

- ENDS -

For further information, please contact:

Aptamer Group plc

Dr Arron Tolley [phone]

SPARK Advisory Partners Limited - Nominated Adviser

Andrew Emmott / Adam Dawes [phone]

Liberum Capital Limited - Broker

Richard Lindley / Ben Cryer / Cara Murphy [phone]

Consilium Strategic Communications

   Matthew Neal / Chris Welsh / Lucy Featherstone                              [phone] 

[e-mail]

About Aptamer Group plc

Aptamer Group develops custom affinity binders through its proprietary Optimer(R) platform to enable new approaches in therapeutics, diagnostics and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers through the use of its proprietary Optimer platform.

Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global antibody market is currently worth over $145.0 billion. Optimer binders are engineered to address many of the issues found with alternative affinity molecules, such as antibodies, and offer new, innovative solutions to bioprocessing, diagnostic and pharmaceutical scientists.

Aptamer Group has successfully delivered projects for global pharma companies, diagnostic development companies, and research institutes covering a range of targets and applications with the objective of establishing royalty-bearing licenses. Through the unique Optimer technology and processes, scientists and collaborators are enabled to make faster, more informed decisions that support discovery and development across the Life Sciences.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCBIGDBBXDDGXX

(END) Dow Jones Newswires

January 24, 2023 02:00 ET (07:00 GMT)